ReviewJournal of clinical medicine2025
Large Language Models for Adverse Drug Events: A Clinical Perspective.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Artificial Intelligence Readiness in Clinical Trial Operations: A Narrative Review and Site-Level Governance Framework.Healthcare (Basel, Switzerland) · 2026Review
- Using Natural Language Processing to Identify Adverse Drug Events Characterized by Medication Replacement in Primary Care Electronic Medical Records: Algorithm and Validation Study.Journal of medical Internet research · 2026Article
- Large Language Models in Adverse Drug Reaction Detection and Pharmacovigilance: A Systematic Review of Current Applications, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2026Review
- Extracting adverse event nature, severity, timelines and resulting interventions from clinical notes of patients receiving CAR-T cell therapy using large language models.PLOS digital health · 2026Article
- Natural language processing to enhance rheumatoid arthritis care in clinical studies: a scoping review of applications, data, approaches, challenges and future directions.Rheumatology international · 2026Article
- Extracting adverse event nature, severity, timelines and resulting interventions from clinical notes of patients receiving CAR-T therapy using large language models.medRxiv : the preprint server for health sciences · 2026Article
- Artificial Intelligence for Opioid Safety Surveillance from Clinical Text: A Clinically Focused Review.Journal of clinical medicine · 2026Review
- Confident but unsupported: auditing large language models against supplied evidence boundaries in drug-induced liver injury assessment.Frontiers in public health · 2026Article
- LLM and CQL computable phenotypes for myocarditis adverse event feature and outcome determinations using patient FHIR data: a feasibility study.Frontiers in digital health · 2026Article
- A comparative study of the performance of different large language models in the Chinese National Pharmacist Licensing Examination.Frontiers in medicine · 2026Article
- Article
- Large Language Models for Drug-Related Adverse Events in Oncology Pharmacy: Detection, Grading, and Actioning.Pharmacy (Basel, Switzerland) · 2025Review
- Real-world pharmacovigilance for anti-Aβ therapies using a large language model.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse drug events (ADEs) significantly impact patient safety and health outcomes. Manual ADE detection from clinical narratives is time-consuming, labor-intensive, and costly. Recent advancements in large language models (LLMs), including transformer-based architectures such as Bidirectional Encoder Representations from Transformers (BERT) and Generative Pretrained Transformer (GPT) series, offer promising methods for automating ADE extraction from clinical data. These models have been applied to various aspects of pharmacovigilance and clinical decision support, demonstrating potential in extracting ADE-related information from real-world clinical data. Additionally, chatbot-assisted systems have been explored as tools in clinical management, aiding in medication adherence, patient engagement, and symptom monitoring. This narrative review synthesizes the current state of LLMs in ADE detection from a clinical perspective, organizing studies into categories such as human-facing decision support tools, immune-related ADE detection, cancer-related and non-cancer-related ADE surveillance, and personalized decision support systems. In total, 39 articles were included in this review. Across domains, LLM-driven methods have demonstrated promising performances, often outperforming traditional approaches. However, critical limitations persist, such as domain-specific variability in model performance, interpretability challenges, data quality and privacy concerns, and infrastructure requirements. By addressing these challenges, LLM-based ADE detection could enhance pharmacovigilance practices, improve patient safety outcomes, and optimize clinical workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.